Other News To Note
• Depomed Inc., of Menlo Park, Calif., said it received a Paragraph IV certification notice of an abbreviated new drug application filed by Actavis Group, of Zug, Switzerland, seeking approval for a generic version of Gralise (gabapentin) 300-mg and 600-mg tablets. Actavis' notice alleges that Depomed's six U.S. patents for Gralise will not be infringed by Actavis' proposed product, or alleges that they are invalid and/or are unenforceable.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST